A Randomized, Double-blind, Placebo ‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Condition: Extensive Stage Small Cell Lung Cancer Interventions: Drug: HLX10; Drug: carboplatin and etoposide; Drug: placebo Sponsor: Shanghai Henlius Biotech Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Research | Small Cell Lung Cancer | Study